VEGFRs were studied as targets of angiogenesis in ovarian carcinoma, resulting in approval of a monoclonal antibody against VEGFA, bevacizumab (Avastin), by The Food and Drug Administration in 2014 [127]; however, these agents were not directed at targeting the lymphogenous spread. This evidence concerns the gene VEGFA and ovarian carcinoma.